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Introduction: The need for performing axillary lymph-node dissection in early breast cancer when the
sentinel lymph node (SLN) is positive has been questioned in recent years. The purpose of this study was
to identify a low-risk subgroup of early breast cancer patients in whom surgical axillary staging could be
avoided, and to assess the probability of having a positive lymph-node (LN).
Methods: We evaluated the cohort of 612 consecutive women affected by early breast cancer. We
considered age, tumor size, histological grade, vascular invasion, lymphatic invasion and cancer subtype
(Luminal A, Luminal B HER-2þ, Luminal B HER-2, HER-2þ, and Triple Negative) as variables for uni-
variate and multivariate analyses to assess probability of there being a positive SLN o nonsentinel lymph
node (NSLN). Chi-square, Fisher's Exact test and Student's t tests were used to investigate the relation-
ship between variables; whereas logit models were used to estimate and quantify the strength of the
relationship among some covariates and SLN or the number of metastases.
Results: A signiﬁcant positive effect of vascular invasion and lymphatic invasion (odds ratios are 4 and 6),
and a negative effect of TN (odds ratios is 10) were noted. With respect to positive NSLN, size alone has a
signiﬁcant (positive) effect on tumor presence, but focusing on the number of metastases, also age has a
(negative) signiﬁcant effect.
Conclusion: This work shows correlation between subtypes and the probability of having positive SLN.
Patients not expressing vascular invasion, lymphatic invasion and, moreover, a triple-negative tumor
subtype may be good candidates for breast conservative surgery without axillary surgical staging.
© 2015 IJS Publishing Group Limited. Published by Elsevier Ltd. All rights reserved.1. Introduction
In recent years, the axillary management of early breast cancernico Rotolo 3, Palermo, Italy.
Marrazzo), emilia.marrazzo@
sca).
ished by Elsevier Ltd. All rights respatients has changed. Patients with a clinically-negative axillae are
offered sentinel lymph node (SLN) biopsy and axillary lymph node
dissection (ALND) only in the presence of positive SLN.
The need for performing ALND when the SLN is positive and the
patient is receiving concurrent adjuvant treatment including
radiotherapy, chemotherapy and/or hormonal therapy has been
questioned in recent years.erved.
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micrometastasis in the SLN (tumor clusters range between 0.2 and
2 mm), axillary dissection can be avoided, thus eliminating com-
plications of axillary surgery with no effect on survival.
Data from the ACOSOG Z0011 trial suggest that ALND may be
omitted in selected patients with one or two positive SLNs. This
obviates the complications related to ALND and provides adequate
surgical staging and comparable loco-regional control and survival
[2,3]. Critics of Z0011 have focused on issues of case selection
arguing that estrogen receptor (ER) negative tumors were under-
represented [4]. They highlight the major dilemma of targeted
management of breast cancer surgical treatment. The worldwide
response to Z0011 cautioned that a policy of no-ALND for SLN-
positive patients should adhere strictly to the Z0011 selection
criteria [4] but without considering biology of the tumor, warning
that the criteria do not take into consideration the biology of the
tumor.
The purpose of this study was to identify a low risk subgroup of
early breast cancer patients inwhom surgical axillary staging could
be avoided, and assess the probability of having a positive lymph-
node (LN).
2. Material and methods
Experimental protocol was approved by the institutional review
committee and meet the guidelines of responsible governmental
agency.
Between January 2006 and December 2012, we retrospectively
evaluated 612 consecutive women affected by early breast cancer.
All patients underwent breast conservative surgery, sentinel
lymph-node biopsy and, in cases of positive sentinel node, axillary
dissection.
A total of 397 patients had SLN localization by radio colloid, 183
by blue dye and 32 by combined techniques as previously reported
by the authors [5e7].
Complete axillary dissection was performed when the sentinel
nodes contained metastases.
All patients were treated with breast conservative surgery fol-
lowed by external-beam radiation therapy on the whole breast
through two tangential ﬁelds (50 plus 10 Gy as a boost to the tumor
bed) with a linear accelerator.
In this analysis, according to the TNM classiﬁcation, LN with
micrometastasis were considered as positive, LN with isolated tu-
mor cells were considered as negative.
Estrogen receptor, progesterone receptor (PgR) and proliferation
index (KI-67,%) status were determined on the basis of immuno-
histochemistry (IHC) staining. Tumors were considered HER-2
positive only if they were either scored as 3 þ by IHC or if they
were 2 þ by IHC and also HER-2 ampliﬁed (ratio >2.0) on the basis
of ﬂuorescence in situ hybridization (FISH) [8,9].
According to different combinations of ER, PgR, KI 67 and HER2
status, all patients were categorized into ﬁve subgroups [10] as
follows: Luminal A-like (ERþ/PgRþ/Ki67 < 14%/HER2-), luminal B
HER2 positive-like (ERþ/PgRþ/Ki67 > 14%/HER2þ), Luminal B
HER2 negative-like (ERþ/PgRþ/Ki67 > 14%/HER2-), HER2 positive-
like (ER-/PgR-/HER2þ), and Triple negative like (ER-/PgR-/HER2-).
3. Statistical analysis
We considered age, tumor size (mm), histological grade (1e3),
vascular invasion, lymphatic invasion and cancer subtype (Luminal
A, Luminal B HER-2þ, Luminal B HER-2, HER-2þ, and Triple
Negative) as variables for univariate and multivariate analyses to
assess probability of there being a positive LN. The univariate
analysis is used to study the distributions of the variables and theirassociationwith positive or negative SLN and NSLN: The Chi-square
or Fisher's Exact tests [11], and the Student's t-test [12] were used
for categorical variables and for continuous variables, respectively.
The multivariate analysis concerns just those variables that are
signiﬁcantly associated with positive or negative SLN and NSLN in
the univariate analyses. A multiple logistic model on NSLN, just to
estimate and quantify the strength of the relationship, and a
multinomial logistic model [13] on the number of metastases
(considered in three classes) were taken into account.
For this study, a p-value <0.05 was considered as statistically
signiﬁcant. The analyses were performed using R software (http://
cran.r-project.org).
4. Results
The median age was 57 (range 29e86 years). Patients charac-
teristics are summarized in Table 1. With respect to all the 612
patients, complete data from 590 patients were available for the
molecular subtype classiﬁcation: 180 patients were luminal A-like
(34.45%), 272 patients were Luminal B HER2 negative-like (46.02%),
46 patients were Luminal B HER2 positive-like (7.78%), 33 patients
was HER2 positive-like (5.58%) and 59 patients were triple
negative-like (TN) (9.98%).
The SLN identiﬁcation rate was 100% irrespective of different
techniques. 391 patients (63.72%) had negative SLN, 35 had isolated
cancer cells, 221 had metastasis (36.28%), of these micrometastases
were detected in 59 patients. Complete ALND was performed in
220 patients, and the median number of dissected Non-Sentinel
Lymph Nodes (NSLN) was 19 (range 9e43). Among these 220 pa-
tients, 89 (40.45%) had at least one positive NSLN.
At univariate analysis (Table 1) tumor size, presence of
lymphatic and vascular invasion and molecular subtype were
signiﬁcantly associated with positivity of SLN (p < 0.0001). Age
(p ¼ 0.124) and grading (p ¼ 0.370) did not show signiﬁcant as-
sociation with positive SLN.
Among molecular subtypes, triple negative showed the higher
rate of SLN negativity than other groups (91.53% vs 8.47%,
p < 0.0001).
The strength of the relationship between the signiﬁcant vari-
ables of Table 1 and SLN was evaluated through a multivariate lo-
gistic regression model.
Baseline characteristics are: no vascular invasion, no lymphatic
invasion, mean tumor Size, and Luminal A Subtype.
Results are reported in Table 2 and Table 3. In Table 2, it is
possible to notice the signiﬁcant effect of all the covariates with the
exception of three subtypes (Luminal B HER-2þ, Luminal B HER-2,
and HER-2þ).
Modeling without subtypes was also performed, but the com-
parison with the previous modeling suggests that subtype be kept
as a covariate (p-value ¼ 0.00015).
A more suitable interpretation of the parameter estimations is
given by their transformation into odds ratios (Table 2). The main
effects are due to lymphatic invasion, vascular invasion, and triple
negative subtype (TN): the odds of positive SN for those who have
lymphatic invasion is 6 times the odds for thosewho do not, and for
those having vascular invasion it is 4 times the odds for those who
do not. Moreover, having TN seems to reduce the odds of positive
SN (the odds of positive SN for those not having TN is 10 times the
odds for those having it), whereas tumor size seems to increase the
odds of positive SN by 8%.
Moreover, we focused on patients with positive SLN and ALND.
In the univariate analysis of NLSN (Table 3), just age and size seem
to be associated with NSLN metastasis, while no relationship with
other variables seems to be signiﬁcant.
If a logistic model is performed on NSLN with age and size, the
Table 1
Clinical and pathologic features of the sentinel node negative and positive tumors.
SLN (612) TOT p-value
Negative 391 (63.72%) Positive 221 (36.28%)
Age (years) 58.25 (13.22) 56.59 (11.95) 57.65 (12.790) 0.124
Size (mm) 15.89 (7.24) 20.19 (8.53) 17.45 (8.00) <0.0001
Grade
1 98 (65.33%) 52 (34.67%) 150 (25.29%) 0.370
2 128 (59.26%) 88 (40.74%) 216 (36.43%)
3 148 (65.2%) 79 (34.80%) 227 (38.28%)
Vascular invasion
0 359 (67.99%) 169 (32.01%) 528 (86.42%) <0.0001
1 30 (36.14%) 53 (63.86%) 83 (13.58%)
Lymphatic invasion
0 (no) 380 (66.09%) 195 (33.91%) 575 (94.11%) <0.0001
1 (yes) 9 (25.00%) 27 (75.00%) 36 (5.89%)
Subtype
Luminal A 117 (65.04) 63 (35.%) 180 (30.54%) <0.0001
Luminal B HER-2þ 29 (63.04%) 17(36.95%) 46 (7.79%)
Luminal B HER-2- 159 (58.45%) 112 (41.17%) 272 (46.10%)
HER-2þ 18 (54.54%) 15 (45.45%) 33 (5.59.00%)
Triple negative 54 (91.53%) 5 (8.47%) 59 (10.00%)
For Age and Size, marginal and conditional means and standard errors (in parentheses) are reported.
For other variables, marginal and conditional counts and percentage (in parentheses and by row) are reported.
The analysis does not account for missing data.
Table 2
Multivariate logistic regression model to predict the probability of SLN metastases.
Coefﬁcients Estimate Std. Error OR (95% C.I.) p-value
(Intercept) 2.14669 0.28488 0.1169 <0.0001
Vascular invasion 1.38190 0.27218 3.9825 <0.0001
Size 0.08172 0.01384 1.0851 <0.0001
Lymph invasion 1.81500 0.43035 6.1411 <0.0001
Luminal B HER-2þ 0.29937 0.37604 0.7413 0.426
Luminal B HER-2- 0.02662 0.22032 0.9737 0.904
HER-2þ 0.20266 0.43444 1.2247 0.641
Triple negative 2.31401 0.53092 0.0989 <0.0001
Table 4
Coefﬁcients estimation and their signiﬁcance for the logit model on NSLN.
Coefﬁcients Estimate Std. Error OR (95% C.I.) p-value
Intercept 0.2591 0.7999 0.7717 0.7460
Age 0.0290 0.0126 0.9714 0.0210
Size 0.0748 0.0199 1.0777 0.000176
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respect to the baseline (Negative NSLN patients, with mean age of
58.15 and mean tumor size of 18.29), the effect of the variables is
different in sign: the higher the age, the lower the odds of having aTable 3
Clinical and pathologic features of the nonsentinel node negative and positive tumors.
NSLN (220)
Negative 131 (59.54%) Po
Age (years) 58.15 (12.05) 54
Size (mm) 18.29 (6.45) 23
Grade
1 31 (59.62%) 21
2 58 (67.44%) 28
3 39 (50.65%) 39
Vascular invasion
Negative 102 (61.45%) 64
Positive 27 (51.92%) 25
Lymphatic Invasion
Negative 116 (60.73%) 75
Positive 13 (48.15%) 14
Subtype
Luminal A 40 (61.53%) 25
Luminal B HER-2þ 7 (36.84%) 12
Luminal B HER-2- 70 (63.66%) 40
HER-2þ 6 (40.00%) 9
Triple negative 3 (60.00%) 2
For Age and Size, marginal and conditional means and standard errors (in parentheses)
For other variables, marginal and conditional counts and percentage (in parentheses and
The analysis does not account for missing data.NSLN metastasis (having a metastasis is 3% more likely among
those are younger), whereas the greater the size of tumor, the
higher the odds of having a NSLN metastasis (more than 7%).
Finally, if the number of metastases is categorized into three
classes (0, 1j-j3, >3), a multinomial logit model on positive NLSN
can be considered with age and size. Results in Table 5 conﬁrm the
previous results, stressing the same effect of age and size on the
odds of having 1j-j3 or >3 metastases with respect to having none:TOT p-value
sitive 89 (40.45%)
.38 (11.15) 56.61 (11.81) 0.0201
.01 (10.20) 20.22 (8.49) <0.0001
(40.38%) 52 (24.19%) 0.09276
(32.56%) 86 (40.00%)
(49.35%) 77 (35.81%)
(38.55%) 166 (76.15%) 0.2903
(48.08%) 52 (23.85%)
(39.27%) 191 (87.61%) 0.3001
(51.85%) 27 (12.39%)
(38.46%) 65 (30.37%) 0.4362
(63.15%) 19 (8.87%)
(36.36%) 110 (51.40%)
(60.00%)) 15 (7.01%)
(40.00%) 5 (2.33%)
are reported.
by row) are reported.
Table 5
Multinomial logistic model to predict the probability of NSLN number of metastases.
NSLN positive Intercept (OR 95% C.I.) Age (OR 95% C.I.) Size (OR 95% C.I.)
1j-j3 0.1749 (0.8385)* 0.0262 (0.9741) 0.0310 (1.0315)
>3 1.8212 (0.1618) 0.0311 (0.9694) 0.1168 (1.1239)
Note: ‘*’ is not signiﬁcant.
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having >3 metastases with respect to having none (12% more
likely).
In summary, the analyses highlight the non-signiﬁcant effect of
age and grade on SLN, a signiﬁcant positive effect of vascular in-
vasion and lymphatic invasion, and a negative effect of TN. With
respect to positive NSLN, only size has a signiﬁcant (positive) effect
on tumor presence, but if we focus on the number of metastases,
also age has a (negative) signiﬁcant effect.5. Discussion
This work shows the correlation between subtypes and proba-
bility of having positive SLN.
Considering results of the present study, patients with early
breast cancer without expression of vascular invasion, lymphatic
invasion and, moreover, triple negative tumor subtype could be
good candidates for breast conservative surgery without axillary
surgical staging.
Recent clinical trials suggest that there is no difference in
outcome between patients with positive SLN if they are treated
with ALND or given no further axillary surgery [2,3,14].
These studies raise doubts concerning the role of SLN biopsy. A
new trial on this topic comparing SLN biopsy with the assessment
of whether an axillary ultrasound is negative in patients with small
breast cancer is actually running [15] so, considering that metas-
tasis is observed in approximately 30% of SLN biopsies [16], it is
important to predict the axillary node status before SLN biopsy.
Agresti et al. [17], recently published a randomized clinical trial
performed in patients with T1N0 breast cancer to test the hy-
pothesis of the non-inferiority of breast conservative surgery
without axillary dissection compared with breast conservative
surgery and complete axillary lymph node dissection, using overall
survival as the primary endpoint. He states an alternative pattern of
adjuvant treatment decision making exclusively based on a set of
pathologic and biological characteristics of the primary tumor.
Additional information regarding axillary lymph node involvement
at the time of breast surgery would not have changed the decision
concerning adjuvant treatment. It is worth noting that this study
was designed before sentinel lymph node biopsy was introduced
into routine clinical practice (1998). Thus, the intriguing question is
what would happen if Agresti et al. reanalyzed the patient data
bank on the basis of the new molecularly deﬁned subentities of
breast cancer (luminal A, luminal B, basal-like, or triple-negative)
determined by ER, progesterone receptor, Ki-67, human
epidermal growth factor receptor 2 (HER2) status. Consequently,
the authors could analyze how the adjuvant strategy might have
been changed and what the resulting impact on OS and DFS was.
Based on current knowledge, there is an urgent need to redeﬁne
lymph node signiﬁcance in the treatment of patients with breast
cancer and there is the need to select which patients may have the
risk of downstaging which may affect the choice of adjuvant
treatments and therefore prognosis.
Various clinicopathological factors have been identiﬁed as in-
dependent predictors of axillary LN metastasis in early stage breast
cancer, lymphatic and vascular involvement, tumor grade, hor-
mone receptor (HR) status, age, molecular subtype classiﬁcationand tumor size [18e32].
Predicting the NSLN status is important because the American
College of Surgeons Oncology Group (ACOSOG) Z0011 trial [2]
indicated that ALND should be avoided if SLN metastases detec-
ted in only one or two nodes showing that SLN biopsy alone
without ALND results in extremely low locoregional recurrence and
excellent overall survival comparable to that in patients undergoing
ALND if SLN metastasis is present.
To predict the association between NSLNmetastasis and clinico-
pathological factors, particularly in the case of SLN metastasis in
two or fewer nodes in breast cancer, is still a matter of debate and it
is so important when making decisions regarding additional ALND
in the case of positive SLN metastasis.
Hasegawa M et al. [33] reported that SLN metastasis was asso-
ciated with younger age, large tumor size and prominent lym-
phovascular involvement; however, NSLN metastasis was hard to
predict using clinicopathological factors.
Previous studies have reported that younger age, higher pT
stage, or lymphovascular involvement are independent predictors
of SLN metastasis [19e25]. With regard to the prediction of NSLN
metastases, younger age, large tumor size or lympho-vascular
involvement have been reported as useful markers. One of the
most important studies is reported by Toshikawa C. et al. [14] that
show that invasive tumor size and lymphatic involvement are
signiﬁcantly associated with NSLN metastasis in the case of SLN
metastasis in two or fewer nodes.
Our ﬁndings show furthermore that age is correlated to NSLN
metastasis but not with SLN metastasis. Tvedskov TF. et al. [34]
identiﬁed increased proportion of NSLN metastasis in patients
with isolated tumor cells into SN in younger age at diagnosiss, thus
that was not conﬁrmed in case of micrometastatic or metastatic SN.
The independent association of age with NSLN metastases and,
in other studies, with poor prognosis has not been explained by the
association of age with other prognostic variables. These results
suggest that surgeons and pathologists should be diligent and
thorough in searching for lymph nodemetastases in young patients
with large tumors or lymphatic invasion.
In a meta-analysis conducted by Lowery AJ et al. [35], loco-
regional recurrence rate varied between different subtypes. In
particular, RR is 0.49 for any luminal subtypes versus TN regarding
breast conservative surgery and of 0.66 regarding mastectomy.
The subtypes may be predictive of loco-regional recurrence and
survival also after post-mastectomy radiotherapy [36], and after
neo-adjuvant chemotherapy [37,38].
Although there is a paucity of data on associations between
presence or extent of nodal diseases across all breast cancer sub-
types, conﬂicting results on the relationship between theTN subtype
and nodal disease have been reported [37,38]. Several publications
suggest that the TN subtype may predict a lower risk of nodal
involvement [18,28,29,31,39] despite Jones T et al. [40] reporting no
association between TN subtype and nodal involvement, presum-
ably because HER-2 2 þ tumors were considered positive without
the FISH test. Possibly this altered the real number of TN.
Although axillary surgery maintains its role in local disease
control in patients with clinically evident lymph node involvement,
biological characteristics of the primary tumor are important for
guiding therapeutic decisions regarding nodal management. Our
results thus provide useful information on the risk factors for
renmant NSLN metastasis under the condition of SLN contributing
to decision-making with regard to the addition of ALND or the kind
of adjuvant therapies in the case of SLN metastasis.
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